title: Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy.
abstract: We showed previously that humanization of 528, a murine anti-epidermal growth factor receptor (EGFR) antibody, causes reduced affinity for its target. Here, to improve the affinity of the humanized antibody for use in cancer immunotherapy, we constructed phage display libraries focused on the complementarity-determining regions (CDRs) of the antibody and carried out affinity selection. Two-step selections using libraries constructed in a stepwise manner enabled a 32-fold affinity enhancement of humanized 528 (h528). Thermodynamic analysis of the interactions between the variable domain fragment of h528 (h528Fv) mutants and the soluble extracellular domain of EGFR indicated that the h528Fv mutants obtained from the first selection showed a large increase in negative enthalpy change due to binding, resulting in affinity enhancement. Furthermore, mutants from the second selection showed a decrease in entropy loss, which led to further affinity maturation. These results suggest that a single mutation in the heavy chain variable domain (i.e. Tyr(52) to Trp) enthalpically contributed for overcoming the energetic barrier to the antigen-antibody interaction, which was a major hurdle for the in vitro affinity maturation of h528. We reported previously that the humanized bispecific diabody hEx3 Db, which targets EGFR and CD3, shows strong anti-tumor activity. hEx3 Db mutants, in which the variable domains of h528 were replaced with those of the affinity-enhanced mutants, were prepared and characterized. In a growth inhibition assay of tumor cells, the hEx3 Db mutants showed stronger anti-tumor activity than that of hEx3 Db, suggesting that affinity enhancement of h528Fv enhances the anti-tumor activity of the bispecific diabody.
authors.affiliation: Department of Biomolecular Engineering, Graduate School of Engineering,  Tohoku University, Aoba-yama 6-6-11, Aoba-ku, Sendai 980-8579,  Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Maru
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tahara
authors.forename: Hideaki
authors.initials: H
authors.lastname: Sanada
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Umetsu
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Asano
authors.forename: Izumi
authors.initials: I
authors.lastname: Kumagai
mesh_terms: D019943:Amino Acid Substitution; D000915:Antibody Affinity; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018920:Coculture Techniques; D022801:Complementarity Determining Regions / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology; D066246:ErbB Receptors / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D020128:Inhibitory Concentration 50; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D009369:Neoplasms / Q000628:therapy*; D019151:Peptide Library; D011485:Protein Binding; D057127:Single-Chain Antibodies / Q000096:biosynthesis* / Q000235:genetics / Q000494:pharmacology; D013816:Thermodynamics
chemical_list: D022801:Complementarity Determining Regions; D019151:Peptide Library; D057127:Single-Chain Antibodies; D066246:ErbB Receptors